Mixed Mesodermal (Mullerian) Tumor

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

8 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

7 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Gemcitabinesmall molecule

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Doxorubicinsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Olaparibsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Adavosertibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bendamustinesmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cisplatinsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Docetaxelsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Elacestrantsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ifosfamidesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ipilimumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nab-paclitaxel

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Topotecansmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Veliparibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor

Mixed Mesodermal (Mullerian) Tumor studied in …STUDIED_INderived10 of 24show all (up to 200)
→ studied in	NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 24 trials mapped (14 active)	—	—	Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ALIAS · 24 trials mapped (14 active)	—	—	Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT02101775Phase 2 · active not recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 24 trials mapped (14 active)	—	—	Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT06580314Phase 3 · recruiting Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 24 trials mapped (14 active)	—	—	Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT04092270Phase 1 · active not recruiting A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 24 trials mapped (14 active)	—	—	Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT02834013Phase 2 · active not recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · condition mapped ONTOLOGY_EXACT · 24 trials mapped (14 active)	—	—	Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT01167712Phase 3 · active not recruiting Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 24 trials mapped (14 active)	—	—	Ovarian Clear Cell Adenocarcinofibroma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07467772Phase 2 · recruiting Ph 2 Elacestrant in ER Positive Uterine Sarcomas · condition mapped ALIAS · 24 trials mapped (14 active)	—	—	Uterine Corpus Adenosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01737619NA · active not recruiting PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 24 trials mapped (14 active)	—	—	Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT04919629Phase 2 · recruiting APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion · condition mapped ALIAS · 24 trials mapped (14 active)	—	—	Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →

Mixed Mesodermal (Mullerian) Tumor studied in …STUDIED_INderived10 of 24show all (up to 200)

→ studied in

NCT05256225Phase 3 · recruiting

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 24 trials mapped (14 active)

—

Observed

Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor

→ studied in

NCT05920798Phase 1/Phase 2 · active not recruiting

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ALIAS · 24 trials mapped (14 active)

—

Observed

Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor

→ studied in

NCT02101775Phase 2 · active not recruiting

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 24 trials mapped (14 active)

—

Observed

Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor

→ studied in

NCT06580314Phase 3 · recruiting

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 24 trials mapped (14 active)

—

Observed

Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor

→ studied in

NCT04092270Phase 1 · active not recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 24 trials mapped (14 active)

—

Observed

→ studied in

NCT02834013Phase 2 · active not recruiting

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · condition mapped ONTOLOGY_EXACT · 24 trials mapped (14 active)

—

Observed

Ovarian Clear Cell Adenocarcinofibroma

→ studied in

NCT01167712Phase 3 · active not recruiting

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 24 trials mapped (14 active)

—

Observed

Uterine Corpus Adenosarcoma

→ studied in

NCT07467772Phase 2 · recruiting

Ph 2 Elacestrant in ER Positive Uterine Sarcomas · condition mapped ALIAS · 24 trials mapped (14 active)

—

Observed

Malignant Mixed Mesodermal (Mullerian) Tumor

→ studied in

NCT01737619NA · active not recruiting

PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 24 trials mapped (14 active)

—

Observed

Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor

→ studied in

NCT04919629Phase 2 · recruiting

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion · condition mapped ALIAS · 24 trials mapped (14 active)

—

Observed